The influence of aged garlic extract on the uptake of saquinavir and darunavir into HepG2 cells and rat liver slices

Drug Metabolism and Pharmacokinetics

Volumn 25, Issue 3, 2010, Pages 307-313

  Berginc, Katja ^a   Trontelj, Jurij ^a   Kristl, Albin ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Aged garlic extract; Darunavir; Efflux transporters; Hepg2 cells; Rat liver slices; Saquinavir

Indexed keywords

CARRIER PROTEIN; DARUNAVIR; GARLIC EXTRACT; GLYCOPROTEIN P; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; MULTIDRUG RESISTANCE PROTEIN 2; RITONAVIR; SAQUINAVIR; MULTIDRUG RESISTANCE PROTEIN; PLANT EXTRACT; SULFONAMIDE;

ANIMAL TISSUE; ARTICLE; BINDING SITE; CELL STRAIN HEPG2; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG BIOAVAILABILITY; DRUG LIVER LEVEL; DRUG TRANSPORT; DRUG UPTAKE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NONHUMAN; RAT; ANIMAL; CYTOLOGY; DRUG EFFECTS; DUODENUM; GARLIC; HEPG2 CELL LINE; HERB DRUG INTERACTION; LIVER; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL; WISTAR RAT;

ANIMALS; BIOLOGICAL TRANSPORT; DUODENUM; GARLIC; HEP G2 CELLS; HERB-DRUG INTERACTIONS; HIV PROTEASE INHIBITORS; HUMANS; LIVER; MALE; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; PLANT EXTRACTS; RATS; RATS, WISTAR; RITONAVIR; SAQUINAVIR; SULFONAMIDES;

EID: 77954346375     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.25.307     Document Type: Article

References (26)

1. Aungst, B. J.: P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugs. Adv. Drug Deliv. Rev., 39: 105-116 (1999).
2. Reed, C. and Daar, E. S.: Novel antiretroviral agents in HIV therapy. Curr. infect. dis. rep., 8: 489-496 (2006).
3. Lee L. S., Andrade, A. S. A. and Flexner, C.: Interactions between natural health products and antiretroviral drugs: pharmacokinetic and pharmacodynamic effects. Curr. infect. dis. rep., 43: 1052-1059 (2006).
4. Mills, E., Montori, V., Perri, D., Philips, E. and Koren, G.: Natural health product-HIV interactions: a systematic review. Int. J. STD AIDS, 16: 181-186 (2005).
5. Foster, B. C., Arnason, J. T. and Briggs, C. J.: Natural health products and drug disposition. Annu. Rev. Pharmacol. Toxicol., 45: 203-226 (2005).
6. Fugh-Berman, A. and Ernst, E.: Herb-drug interactions: review and assessment of report reliability. Br. J. Clin. Pharmacol., 52: 587-595 (2001).
7. Piscitelli, S. C., Burstein, A. H., Welden, N., Gallicano, K. D. and Falloon, J.: The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin. infect. dis., 34: 234-238 (2002).
8. Prezista®, Janssen-Cilag Ltd, Summary of product characteristics;http:/emc.medicines.org.uk/
9. Vermeir, M., Lachau-Durand, S., Mannens, G., Cuyckens, F., van Hoof, B. and Raoof, A.: Absorption, metabolism and excretion of darunavir, a new protease inhibitor, administered alone and with low-dose ritonavir in healthy subjects. Drug Metab. Dispos., 37: 809-820 (2009).
10. Alexandre, E., David, P., Viollon, C., Wolf, P., Jaeck, D., Azimzadeh, A., Nicod, L., Boudjema, K. and Richert, L.: Expression of Cytochromes P-450 2E1, 3A4 and 1A1/1A2 in Growing and Confluent Human HepG2 Hepatoma Cells-Effect of Ethanol. Toxicol. in vitro, 13: 427-435 (1996).
11. Hilgendorf, C., Ahlin, G., Seithel, A., Artursson, P., Ungell, A. L. and Karlsson, J.: Expression of Thirty-six Drug Transporter Genes in Human Intestine, Liver, Kidney, and Organotypic Cell Lines. Drug Metab. Dispos., 35: 1333-1340 (2007).
12. Berginc, K., Žakelj S., Uršič, D. and Kristl, A.: Aged garlic extract stimulates P-glycoprotein and multidrug resistance associated protein 2 mediated effluxes. Biol. Pharm. Bull., 32: 694-699 (2009).
13. Hawkins, B. T., Ocheltree S. M., Norwood, K. M. and Egleton, R. D.: Decreased blood-brain barrier permeability to fluorescein in streptozotocin-treated rats. Neurosci. Lett., 411: 1-5 (2007).
14. Berginc, K., Žakelj S. and Kristl, A.: In vitro interactions between aged garlic extract and drugs used for the treatment of cardiovascular and diabetic patients. Eur. J. Nutr. 2010, accepted for publication.
15. Williams G. C., Liu, A., Knipp, G. and Sinko, P. J.: Direct Evidence that Saquinavir Is Transported by Multidrug Resistance Associated Protein (MRP1) and Canalicular Multispecific Organic Anion Transporter (MRP2). Antimicrob. Agents Chemother., 46: 3456-3462 (2002).
16. Gupta, A., Zhang, Y., Unadkat, J. D. and Mao, Q.: HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J. Pharmacol. Exp. Ther., 310: 334-341 (2004).
17. Buss, N., Snell, P., Bock, J., Hsu, A. and Jorga, K.: Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) aministration. Br. J. Clin. Pharmacol., 52: 255-264 (2001).
18. Usansky, H. H., Hu, P. and Sinko, P. J.: Differential Roles of PGlycoprotein, Multidrug Resistance-Associated Protein 2, and CYP3A on Saquinavir Oral Absorption in Sprague-Dawley Rats. Drug metab. dispos., 36: 863 - 869 (2008).
19. Wu, C. Y. and Benet, L. Z.: Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of Biofarmaceutical drug disposition classification system. Pharm. Res., 22: 11-23 (2005).
20. Sekar, V., Kestens, D., Spinosa-Guzman, S., De Pauw, M., De Paepe, E., Vangeneugden, T., Lefebvre, E. and Hoetelmans, R. M. W.: The Effect of Different Meal Types on the Pharmacokinetics of Darunavir (TMC114)/Ritonavir in HIV-Negative Healthy Volunteers. J. Clin. Pharmacol., 47: 479-484 (2007).
21. Drewe, J., Gutmann, H., Fricker, G., Toäroäk, M., Beglinger, C. and Huwyler, J.: HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than cyclosporine analog SDZ PSC 833. Biochem. Pharmacol., 57: 1147-1152 (1999).
22. Fujimoto, H., Higuchi, M., Watanabe, H., Koh, Y., Ghosh, A. K., Mitsuya, H., Tanoue, N., Hamada, A. and Saito, H.: PGlycoprotein Mediates Efflux Transport of Darunavir in Human Intestinal Caco-2 and ABCB1 Gene-Transfected Renal LLC-PK1 Cell Lines. Biol. Pharm. Bull., 32: 1588-1593 (2009).
23. Villanueva, S. M. S., Ruiz, M. L., Luquita, M. G., Pozzi E. J. S., Catania, V. A. and Mottino, A. D.: Involvement of Mrp2 in Hepatic and Intestinal Disposition of Dinitrophenyl-Sglutathione in Partially Hepatectomized Rats. Toxicol. Sci., 84: 4-11 (2005).
24. Payen, L., Sparfel, L., Courtois, A., Vernhet, L., Guillouzo, A. and Fardel, O.: The drug efflux pump MRP-2: Regulation of expression in physiopathological situations and by endogenous and exogenous compounds. Cell Biol. Toxicol., 18: 221-233 (2002).
25. Tanaka, Y., Kobayashi, Y., Gabazza, E. C., Higuchi, K., Kamisako, T., Kuroda, M., Takeuchi, K., Iwasa, M., Kaito, M. and Adachi, Y.: Increased renal expression of bilirubin glucuronide transporters in a rat model of obstructive jaundice. Am. J. Physiol. Gastrointest. Liver Physiol., 282: G656-G662 (2002).
26. Foster, B., Foster, M., Vandenhoek, S., Krantis, A., Budzinski, J. W., Arnason, J. T., Gallicano, K. D. and Choudri, S.: An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J. Pharm. Pharmaceut. Sci., 4: 176-184 (2001).